Migraine, cholesterol upstarts top the list of FDA decisions to watch this quarter

It's a new year, which means it's a new opportunity for drugmakers hoping to pass FDA muster for new therapies––some of which could be sniffing after blockbuster sales.

In the first quarter, the FDA is set to decide on a group of new drugs that come with high hopes, high scrutiny and, in some cases, raised eyebrows from the agency staff who have reviewed them.